ASCO 2023 | Increasing T cell responses in HPV16+ oropharyngeal cancer with TheraT vectors

Ari Rosenberg, MD, Yale School of Medicine, New Haven, CT, provides an overview of the Phase I/II trial (NCT05108870) of TheraT vectors with neoadjuvant chemotherapy followed by chemoradiotherapy in patients with HPV16+ oropharyngeal cancer (OPC). TheraT vectors is a HPV specific immune therapy that aim to increase the production of HPV16 T cells to reduce toxicity associated with chemoradiotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.